Research Publications
2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. 2019.
Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.
Dessinioti C, Dimou N, Geller A, Stergiopoulou A, Lo S, Keim U et al. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. JNCI: Journal of the National Cancer Institute. 2019.
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Lee J, Saw R, Thompson J, Lo S, Spillane A, Shannon K et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology. 2019.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019.
Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials.
Edwards J, Tasker A, Silva I, Quek C, Batten M, Ferguson A et al. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials. Clinical Cancer Research. 2019.
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. 2019.
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.
Kim H, Duong J, Gonzalez M, Long G, Menzies A, Rizos H et al. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology. 2019.